We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BION.SW

Price
41.65
Stock movement up
+0.30 (0.73%)
Company name
BB Biotech AG
Exchange
(SW
,
Currency
CHF
)
Sector
Healthcare >
Biotechnology
Market cap
2.30B
Ent value
2.30B
Price/Sales
-
Price/Book
1.25
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
8.48
PEG
-
EPS growth
-35.32%
1 year return
4.52%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-11-14

DIVIDENDS

BION.SW does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF5.27
Price to FCF5.94
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book1.25
EV to Sales-13.04

FINANCIALS

Per share

Loading...
Per share data
Current share count55.15M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)4.91

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.16M
Net receivables0.00
Total current assets1.84B
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets1.84B
Accounts payable0.00
Short/Current long term debt0.00
Total current liabilities2.43M
Total liabilities2.43M
Shareholder's equity1.84B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open40.95
Daily high41.65
Daily low40.35
Daily Volume94K
All-time high179.00
1y analyst estimate47.70
Beta0.70
EPS (TTM)-
Dividend per share0.00
Ex-div date21 Mar 2025
Next earnings date20 Feb 2026

Downside potential

Loading...
Downside potential data
BION.SWS&P500
Current price drop from All-time high-76.73%-2.25%
Highest price drop-85.89%-19.00%
Date of highest drop9 Apr 20258 Apr 2025
Avg drop from high-80.68%-2.71%
Avg time to new high-5 days
Max time to new high276 days89 days
COMPANY DETAILS
BION.SW (BB Biotech AG) company logo
Marketcap
2.30B
Marketcap category
Mid-cap
Description
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Employees
10
Investor relations
-
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproli...
November 10, 2025
SCHAFFHAUSEN, Switzerland - September 22, 2025 (NEWMEDIAWIRE) - BB Biotech AG announces that it will be included in the SPI ESG Index of the SIX Swiss Exchange as of today, September 22, 2025. This hi...
September 22, 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
September 9, 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
September 9, 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
September 9, 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
September 9, 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
September 9, 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
September 9, 2025